StreetInsider.com News Articles

Form PRE 14A Nexentis Technologies For: Mar 02

Mon, 02 Mar 2026 07:29:00 -0500

si-local-file:///var/storage/secattach/20260302/26086966.html

Form PRE 14A Nexentis Technologies For: Mar 02

Mon, 02 Mar 2026 07:29:00 -0500

si-local-file:///var/storage/secattach/20260302/26086966.html

Form 8-K Nexentis Technologies For: Feb 26

Thu, 26 Feb 2026 16:27:00 -0500

si-local-file:///var/storage/secattach/20260226/26071480.html

Form 8-K Nexentis Technologies For: Feb 26

Thu, 26 Feb 2026 16:27:00 -0500

si-local-file:///var/storage/secattach/20260226/26071480.html

Form 8-K N2OFF, Inc. For: Feb 25

Wed, 25 Feb 2026 09:31:00 -0500

si-local-file:///var/storage/secattach/20260225/26056656.html

Form 8-K N2OFF, Inc. For: Feb 25

Wed, 25 Feb 2026 09:31:00 -0500

si-local-file:///var/storage/secattach/20260225/26056656.html

N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company

Wed, 25 Feb 2026 08:30:00 -0500

New identity reflects Company’s evolution into an innovative data driven biotech company leveraging MITOLINE^™ and mitochondrial carrier biology across oncology and inflammatory metabolic diseases

Neve Yarak, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today announced a comprehensive corporate rebranding to Nexentis Technologies Inc. (“Nexentis”) and change in the trading symbol of the Company to “NXTS” on the Nasdaq Capital Market. The name change and

N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company

Wed, 25 Feb 2026 08:30:00 -0500

Form SCHEDULE 13G/A N2OFF, Inc. Filed by: Pierri Ciro Leonardo

Tue, 24 Feb 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260224/26051411.html

Form SCHEDULE 13G/A N2OFF, Inc. Filed by: Pierri Ciro Leonardo

Tue, 24 Feb 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260224/26051411.html

Form SCHEDULE 13G N2OFF, Inc. Filed by: Pierri Ciro Leonardo

Thu, 12 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260212/25991730.html

Form SCHEDULE 13G N2OFF, Inc. Filed by: Pierri Ciro Leonardo

Thu, 12 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260212/25991730.html

N2OFF subsidiary shows anti-inflammatory results in lab tests

Thu, 12 Feb 2026 07:25:55 -0500

N2OFF Inc. (NASDAQ: NITO) announced that its subsidiary MitoCareX Bio Ltd. reported preliminary in vitro data showing reduced inflammatory markers in human immune cells using small-molecule candidates developed through its MITOLINE algorithm.

The biotechnology company tested a library of small-molecule candidates targeting human mitochondrial carriers in laboratory assays designed to measure mitochondrial function, inflammatory signaling, and metabolic responses. Selected candidates demonstrated reduction of inflammatory markers in human immune cells, according to the company's statement.

MitoCareX Bio develops drugs targeting the mitochondrial SLC25 protein family for cancer and other diseases. The company's MITOLINE algorithm creates 3D comparative models of mitochondrial carrier proteins to

N2OFF subsidiary shows anti-inflammatory results in lab tests

Thu, 12 Feb 2026 07:25:55 -0500

MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases

Thu, 12 Feb 2026 07:25:00 -0500

MITOLINE^™Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030

Neve Yarak, Israel, Feb. 12, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced that MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary, has shown

MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases

Thu, 12 Feb 2026 07:25:00 -0500

Form 4 N2OFF, Inc. For: Feb 09 Filed by: Zakai Shlomo

Wed, 11 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260211/25983226.html

Form 4 N2OFF, Inc. For: Feb 09 Filed by: Zakai Shlomo

Wed, 11 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260211/25983226.html

Form 4 N2OFF, Inc. For: Feb 09 Filed by: Palach David

Wed, 11 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260211/25983227.html

Form 4 N2OFF, Inc. For: Feb 09 Filed by: Palach David

Wed, 11 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260211/25983227.html

Form 4 N2OFF, Inc. For: Feb 09 Filed by: Weiss Amitay

Wed, 11 Feb 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260211/25983216.html

Form 4 N2OFF, Inc. For: Feb 09 Filed by: Weiss Amitay

Wed, 11 Feb 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260211/25983216.html

Form 4 N2OFF, Inc. For: Feb 09 Filed by: Barda Lital

Wed, 11 Feb 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260211/25983217.html

Form 4 N2OFF, Inc. For: Feb 09 Filed by: Barda Lital

Wed, 11 Feb 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260211/25983217.html

Taurus Gold Corp. Management Updates

Mon, 09 Feb 2026 08:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - Taurus Gold Corp. (CSE: TAUR) ("Taurus" or the "Company") announces management changes at Taurus.

Mr. Robert Sim resigned his position as Director and CEO of Taurus, effective February 7, 2026.

Mr. Asaf Itzhaik has been appointed by the Board of Directors as a director, effective February 7, 2026.

Mr. Nissim Daniel, Director of Taurus, has been appointed by the Board of Directors as the CEO, effective February 7, 2026.

Asaf Itzhaik brings an impressive background spanning 30 years managing an acclaimed Israeli optic brand that specializes in serving athletes. With a wealth of experience in